

## Datasheet: BUF029

**BATCH NUMBER 159197**

<b>Description:</b>	BLOCK ACE
<b>Name:</b>	BLOCK ACE
<b>Format:</b>	Reagent
<b>Product Type:</b>	Accessory Reagent
<b>Quantity:</b>	20 x 4g

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			1/4
Western Blotting	▪			Neat

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the reagent for use in their own system using appropriate negative/positive controls

### Reconstitution

Reconstitute each 4g sachet in 100ml distilled water.

### Product Information

Block Ace is designed as a high-performance blocking reagent for use in immunological assays such as ELISA and Western blotting. It may also be used for dilution of antibodies and for washing procedures in the above assays.

Block Ace has been shown to have superior performance to 1% BSA in blocking in ELISA assays. In comparison to BSA, Block Ace provides reduced backgrounds and sharper standard curves.

For blocking in ELISA applications, we recommend using a 1/4 dilution of the reconstituted solution.

For blocking in Western Blotting applications, we recommend using the reconstituted solution neat.

For washing applications we recommend a 1/10 dilution of the reconstituted solution, and adding Tween 20 to a level of 0.05-0.2% v/v.

For use as a test sample or secondary antibody diluent we recommend a 1/10 dilution of the reconstituted solution.

## References

1. Yamashita, M. *et al.* (2010) Morphological and extracellular matrix changes following vocal fold injury in mice. [Cells Tissues Organs. 192 \(4\): 262-71.](#)
2. Head, E. *et al.* (2010) Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. [J Alzheimers Dis. 2010;20\(2\):637-46.](#)
3. Hara, H. *et al.* (1990) Enzyme immunoassay for measuring antibodies against skeletal muscle in patients with myasthenia gravis. [Clin Chem. 36 \(11\): 1967-9.](#)
4. Shinmoto, H. *et al.* (1988) Production of pentameric hybrid immunoglobulins consisting of IgA and IgM. *Agric. Biol. Chem.* 52:2653-2654.
5. Ahmed, R.R. *et al.* (2010) BACE1 and BACE2 enzymatic activities in Alzheimer's disease. [J Neurochem. 112: 1045-53.](#)
6. Matsui, T.S. *et al.* (2011) Non-muscle myosin II induces disassembly of actin stress fibres independently of myosin light chain dephosphorylation. [Interface Focus. 1 \(5\): 754-66.](#)
7. Zhang, B. *et al.* (2012) The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. [J Neurosci. 32 \(11\): 3601-11.](#)
8. Fitz, N.F. *et al.* (2012) Abca1 Deficiency Affects Alzheimer's Disease-Like Phenotype in Human ApoE4 But Not in ApoE3-Targeted Replacement Mice. [J Neurosci. 32: 13125-36.](#)
9. Habara, P. *et al.* (2012) Novel flow cytometric method for the detection of podocalyxin-positive elements in urine of patients with glomerulonephritides - first promising results. [Folia Biol \(Praha\). 58: 57-63.](#)
10. Yamashita, M. *et al.* (2009) Surgical method to create vocal fold injuries in mice. [Ann Otol Rhinol Laryngol. 118: 131-8.](#)
11. Kim, J.A. *et al.* (2015) Magnetic bead droplet immunoassay of oligomer amyloid  $\beta$  for the diagnosis of Alzheimer's disease using micro-pillars to enhance the stability of the oil-water interface. [Biosens Bioelectron. 67: 724-32.](#)
12. Wilcock, D.M. *et al.* (2015) Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease. [Neurobiol Aging. 36 \(9\): 2468-74.](#)
13. Tarhan, Y.E. *et al.* (2016) Morphological Changes, Cadherin Switching, and Growth Suppression in Pancreatic Cancer by GALNT6 Knockdown [Neoplasia 18: 265-72.](#)
14. Hashitani, H. *et al.* (2015) Pacemaker role of pericytes in generating synchronized spontaneous Ca<sup>2+</sup> transients in the myenteric microvasculature of the guinea-pig gastric antrum. [Cell Calcium. 58 \(5\): 442-56.](#)
15. Wilcock DM *et al.* (2015) Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease. [Neurobiol Aging. 36 \(9\): 2468-74.](#)
16. Faraj SF *et al.* (2015) Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. [Urology. 85 \(3\): 703.e1-6.](#)
17. Park, M.C. *et al.* (2016) Droplet-based magnetic bead immunoassay using microchannel-connected multiwell plates ( $\mu$ CHAMPs) for the detection of amyloid beta oligomers. [Lab Chip. 16 \(12\): 2245-53.](#)
18. Kanzaki, H. *et al.* (2017) Phosphoglycerol dihydroceramide, a distinctive ceramide

produced by Porphyromonas gingivalis, promotes RANKL-induced osteoclastogenesis by acting on non-muscle myosin II-A (Myh9), an osteoclast cell fusion regulatory factor.

[Biochim Biophys Acta. 1862 \(5\): 452-462.](#)

19. Qosa, H. *et al.* (2015) Extra-virgin olive oil attenuates amyloid- $\beta$  and tau pathologies in the brains of TgSwDI mice. [J Nutr Biochem. 26 \(12\): 1479-90.](#)

20. Gibbons, G.S. *et al.* (2020) Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer's disease. [Mol Neurodegener. 15 \(1\): 64.](#)

21. Ling, C. *et al.* (2019) Differentiated fibrocytes assume a functional mesenchymal phenotype with regenerative potential. [Sci Adv. 5 \(5\): eaav7384.](#)

22. Marotta, N.P. *et al.* (2021) Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro. [Acta Neuropathol Commun. 9 \(1\): 188.](#)

---

**Storage**

Store at +4°C. DO NOT FREEZE.

This product should be stored undiluted. Should this product contain a precipitate we recommend microcentrifugation before use.

---

**Guarantee**

Guaranteed for 1 week from the date of reconstitution or until the date of expiry, whichever comes first. Please see label for expiry date.

---

**Health And Safety Information**

Material Safety Datasheet documentation #10157 available at: <https://www.bio-rad-antibodies.com/SDS/BUF029>  
10157

---

**Regulatory**

For research purposes only

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)  
'M357871:190910'

**Printed on 25 Jun 2024**

---

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)